Lineage Cell Therapeutics, Inc. (LCTX) 追踪市盈率为负值 -5.6, 表示公司目前在过去十二个月 (TTM) 基础上处于亏损状态。 前瞻市盈率 203.8 基于分析师预估，预计将恢复盈利。 追踪盈利收益率为 -17.87%, 前瞻盈利收益率 0.49%. PEG 0.34 (Peter Lynch 低估标准 ≤1.0).
本页证实的标准:
SharesGrow 综合评分： 48/100 其中 2/7 项标准通过。
| Year | P/E (TTM) | PEG 比率 | P/B 比率 | P/S 比率 | 股息收益率 |
|---|---|---|---|---|---|
| 2016 | 10.5 | -0.07 | 2.98 | 156.00 | - |
| 2017 | -12.3 | 0.08 | 1.51 | 137.35 | - |
| 2018 | -2.5 | -0.02 | 1.23 | 81.55 | 29.80% |
| 2019 | -11.1 | 0.14 | 1.15 | 87.63 | 0.14% |
| 2020 | -12.8 | -0.18 | 2.75 | 341.63 | - |
| 2021 | -9.4 | -0.11 | 4.37 | 103.45 | - |
| 2022 | -7.6 | 0.18 | 2.71 | 13.51 | - |
| 2023 | -8.8 | 0.44 | 2.97 | 21.04 | - |
| 2024 | -5.4 | 0.24 | 1.28 | 10.59 | - |
| 2025 | -6.0 | -0.03 | 8.63 | 26.40 | - |
| Year | EPS（稀释） | 营收 | 净利润 | 净利润率 |
|---|---|---|---|---|
| 2016 | $0.34 | $2.25M | $33.57M | 1490.8% |
| 2017 | $-0.17 | $1.79M | $-19.98M | -1114.7% |
| 2018 | $-0.36 | $1.42M | $-45.99M | -3247.9% |
| 2019 | $-0.08 | $1.48M | $-11.83M | -800.2% |
| 2020 | $-0.14 | $773K | $-20.69M | -2675.9% |
| 2021 | $-0.23 | $3.9M | $-38.56M | -989.8% |
| 2022 | $-0.16 | $14.7M | $-26.35M | -179.2% |
| 2023 | $-0.12 | $8.95M | $-21.49M | -240.2% |
| 2024 | $-0.09 | $9.5M | $-18.61M | -195.9% |
| 2025 | $-0.28 | $14.56M | $-63.53M | -436.5% |
| Year | EPS（平均） | EPS 范围 | 营收（平均） | 营收范围 | 分析师人数 |
|---|---|---|---|---|---|
| 2026 | $-0.04 | $-0.06 – $-0.03 | $29.89M | $13.21M – $46.99M | 4 |
| 2027 | $-0.08 | $-0.16 – $0.03 | $14.92M | $3.65M – $32.39M | 4 |
| 2028 | $0.01 | $-0.05 – $0.18 | $54.87M | $53.42M – $56.32M | 6 |
| 2029 | $0.12 | $0.01 – $0.27 | $76.67M | $24.12M – $150.08M | 4 |
| 2030 | $0.40 | $0.04 – $0.89 | $37.98M | $11.95M – $74.34M | 2 |
